Acorda Therapeutics to Regain Global Commercialization Rights to FAMPYRA® by January 2025

Stock Information for Acorda Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Acorda Therapeutics Inc.

Acorda Therapeutics and Merz Announce Signing of "Stalking Horse" Asset Purchase Agreement
Acorda Cancels Q4 and Year End 2023 Earnings Conference Call Scheduled for April 1, 2024
Acorda Fourth Quarter/Year End 2023 Update: Webcast/Conference Call Scheduled for April 1, 2024
Acorda Therapeutics Reports Third Quarter 2023 Financial Results
Acorda Third Quarter 2023 Update: Webcast/Conference Call Scheduled for November 13, 2023
Acorda Therapeutics Announces Biopas Laboratories Submission to Regulatory Agencies in Six Latin American Countries for Approval of INBRIJA®
Acorda Therapeutics Reports Second Quarter 2023 Financial Results
Acorda Therapeutics Announces Launch of New INBRIJA® Campaign: "For The Fighters(TM)"

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.